Nektar Therapeutics Up After Leukemia Candidate Found Beneficial in Early-Stage Study
Nektar Announces Publication In Blood Of Phase 1 Data For Novel IL-15 Agonist NKTR-255 In Combination With Autologous CD19-22 CAR-T Cell Therapy In Patients With B-cell Acute Lymphoblastic Leukemia
Nektar Announces Publication in Blood of Phase 1 Data for Novel IL-15 Agonist NKTR-255 in Combination With Autologous CD19-22 CAR-T Cell Therapy in Patients With B-cell Acute Lymphoblastic Leukemia
Nektar Rises 11% as BTIG Initiates Buy Rating on Autoimmune Disorders Asset
BTIG Initiates Nektar Therapeutics(NKTR.US) With Buy Rating, Announces Target Price $4
Nektar Therapeutics Analyst Ratings
Express News | Nektar Therapeutics : Btig Assumes Coverage With Buy Rating; Target Price $4
Nektar Therapeutics Announced Several Presentations For Rezpegaldesleukin At The 2024 European Academy Of Dermatology And Venereology Congress
Nektar Therapeutics Announces Multiple Presentations for Rezpegaldesleukin at EADV 2024
Iambic Therapeutics Announces the Addition of Dr. Mary Tagliaferri to Its Board of Directors
Nektar Management to Present at Upcoming Investor Conferences
Nektar Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Nektar Therapeutics | 10-Q: Q2 2024 Earnings Report
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
Nektar Therapeutics Q2 2024 GAAP EPS $(0.25) Misses $(0.21) Estimate, Sales $23.489M Beat $17.545M Estimate
Express News | Nektar Therapeutics: Cash & Marketable Securities Are Expected to Support Strategic Development Activities & Operations Into Q3 of 2026
Nektar Therapeutics (NKTR) Reports Q2 Loss, Tops Revenue Estimates
Earnings Flash (NKTR) NEKTAR THERAPEUTICS Reports Q2 Revenue $23.5M, Vs. Street Est of $17.6M
Express News | Nektar Therapeutics Reports Second Quarter 2024 Financial Results
Express News | Nektar Therapeutics Q2 Net Income USD -52.363 Million